PharmacoEconomics

A Systematic Review of Utility Values for Chemotherapy-Related Adverse Events

Fatiha H. Shabaruddin, Li-Chia Chen, Rachel A. Elliott, Katherine Payne

Correspondence: Katherine Payne, Manchester Centre for Health Economics, Institute of Population Health, The University of Manchester, Jean McFarlane Building, Oxford Road, Manchester, M13 9PL, UK
e-mail: katherine.payne@manchester.ac.uk

Electronic Supplementary Material

Appendix 1

Search strategy used to identify relevant studies in MEDLINE (1948 to June 2011) and EMBASE (1980 to June 2011)

# ▲	Searches	Results
1	utility.af.	186379
2	util$.af.	1008976
3	value$.af.	2502131
4	valuation$.af.	7134
5	1 or 2 or 3 or 4	3409995
6	time trade-off.af.	1178
7	TTO.af.	962
8	(time adj2 trade adj2 off).af.	1195
9	time-trade-off.af.	1178
10	6 or 7 or 8 or 9	1671
11	person trade-off.af.	73
12	PTO.af.	935
13	(person adj2 trade adj2 off).af.	73
14	person-trade-off.af.	73
15	11 or 12 or 13 or 14	974
16	standard gamble.af.	1164
17	SG.af.	10659

18	(standard adj2 gamble).af.	▶	1183
19	16 or 17 or 18	▶	11454
20	visual analogue scale$.af.	▶	24242
21	VAS.af.	▶	53364
22	(visual adj2 analogue adj2 scale).af.	▶	20978
23	20 or 21 or 22	▶	68027
24	judgement$.af.	▶	21480
25	10 or 15 or 19 or 23 or 24	▶	102603
26	cancer.af.	▶	3258392
27	chemotherapy.af.	▶	670583
28	cytotoxic.af.	▶	261196
29	exp cancer/	▶	4805049
30	26 or 27 or 28 or 29	▶	5763132
31	5 and 25 and 30	▶	1824
32	limit 31 to english language	▶	1526
33	limit 32 to human	▶	1279
34	**remove duplicates from 33**	▶	**865**

Appendix 2

Flow diagram of systematic review



Appendix 3: Utility values for chemotherapy-related adverse events obtained from the 18 studies identified (218 values)

Nausea and/or vomiting (32 values)	Mean utility value for adverse event	Variation around mean	Base state/Comparison state	Mean utility for comparison state	Variation around mean	Valua-tion method	Study sample (n)	Study (year)
limited nausea and limited vomiting	Utility increment + 0.53*[a]	Not reported	Base state: Continuous nausea and vomiting	0.53 [a]	Not reported	SG	Patients (n=96)	Grunberg, et al (2009)
limited nausea	Utility increment + 0.55*[a]	Not reported	Base state: Continuous nausea and vomiting	0.53 [a]	Not reported	SG	Patients (n=96)	Grunberg, et al (2009)
limited vomiting	Utility increment + 0.50*[a]	Not reported	Base state: Continuous nausea and vomiting	0.53 [a]	Not reported	SG	Patients (n=96)	Grunberg, et al (2009)
nausea and vomitting	Utility decrement -0.04802	se: 0.01618	Base state: stable disease with no toxicity	0.653	s.e:0.022 23	SG	Public: UK (n=100)	Nafees et al (2008)
nausea/vomiting (grade I/II)	Utility decrement -0.10	se: 0.01	Base state: Partial response	0.88	se: 0.01	SG	Public:Australian (n=77),UK (n=63)	Beusterien et al (2009)
nausea/vomiting (grade I/II)	Utility decrement -0.07	se: 0.01	Base state: Partial response	0.85	se: 0.01	SG	Public: UK (n=63)	Beusterien et al (2009)
nausea/vomiting (grade I/II)	Utility decrement -0.12	se: 0.01	Base state: Partial response	0.91	se: 0.01	SG	Public: Australian(n=77)	Beusterien et al (2009)
nausea/vomiting (grade I/II) with no change	0.73	sd: 0.16	No Change	0. 78	sd: 0.14	SG	Public: England (n=59) Scotland (n=30)	Beusterien et al (2010)[b]
nausea/vomiting (grade I/II) with no change	0.70	sd: 0.16	No Change	0. 76	sd: 0.15	SG	Public: England (n=59)	Beusterien et al (2010)[b]
nausea/vomiting (grade I/II) with no change	0.78	sd: 0.15	No Change	0. 83	sd: 0.11	SG	Public: Scotland (n=30)	Beusterien et al (2010)[b]
nausea (grade I/II) with no change	0.73	sd: 0.17	No change	0. 78	sd: 0.14	SG	Public: England (n=59) Scotland (n=30)	Beusterien et al (2010)[b]
nausea (grade I/II) with no change	0.70	sd: 0.17	No Change	0. 76	sd: 0.15	SG	Public: England (n=59)	Beusterien et al (2010)[b]
nausea (grade I/II) with no change	0.78	sd: 0.16	No Change	0. 83	sd: 0.11	SG	Public: Scotland (n=30)	Beusterien et al (2010)[b]
some post chemotherapy nausea and vomiting (for one to 3 days)	0.942	sd: 0.0742	No post chemotherapy nausea and vomiting	0.968	sd: 0.058	SG	Public: women (n=18)	Franic et al (2003)

Appendix 3: Utility values for chemotherapy-related adverse events

some post chemotherapy nausea and vomiting (for one to 3 days)	0.49	sd: 0.165	No post chemotherapy nausea and vomiting	0.741	sd: 0.155	VAS	Public: women (n=18)	Franic et al (2003)
some post chemotherapy nausea and vomiting (for rest of life)	0.810	sd: 0.141	No post chemotherapy nausea and vomiting	0.927	sd: 0.066	SG	Public: women (n=18)	Franic et al (2003)
some post chemotherapy nausea and vomiting (for rest of life)	0.307	sd: 0.215	No post chemotherapy nausea and vomiting	0.676	sd: 0.225	VAS	Public: women (n=18)	Franic et al (2003)
major post chemotherapy nausea and vomiting (for one to 3 days)	0.866	sd: 0.138	No post chemotherapy nausea and vomiting	0.968	sd:0.058	SG	Public: women (n=18)	Franic et al (2003)
major post chemotherapy nausea and vomiting (for one to 3 days)	0.276	sd: 0.164	No post chemotherapy nausea and vomiting	0.741	sd: 0.155	VAS	Public: women (n=18)	Franic et al (2003)
major post chemotherapy nausea and vomiting (for rest of life)	0.644	sd: 0.243	No post chemotherapy nausea and vomiting	0.927	sd:0.066	SG	Public: women (n=18)	Franic et al (2003)
major post chemotherapy nausea and vomiting (for rest of life)	0.136	sd: 0.135	No post chemotherapy nausea and vomiting	0.676	sd: 0.225	VAS	Public: women (n=18)	Franic et al (2003)
continuous post chemotherapy nausea and vomiting for one year (overall mean)	0.565	Not reported	No vomiting	0.88 (overall mean)	Not reported	SG	Patients & healthcare professionals (n=10)	Grunberg et al (2002)
continuous post chemotherapy nausea and vomiting for one year (with 6 years OS)	0.67	range: 0.05 to 0.95	No vomiting	0.89 (with 6 years OS)	range: 0.65-0.95	SG	Patients & healthcare professionals (n=10)	Grunberg et al (2002)
continuous post chemotherapy nausea and vomiting for one	0.46	range: 0 to 0.95	No vomiting	0.875 (with 2 years OS)	range: 0.75-0.95	SG	Patients & healthcare professionals	Grunberg et al (2002)

Appendix 3: Utility values for chemotherapy-related adverse events

year (with 2 years OS)							(n=10)	
nausea/vomiting (grade I/II)	0.65	sd: 0.15	No comparison state (anchored to 1 for chemotherapy patient)	-	-	TTO	Patients: women (n=13)	Havrilesky et al (2009)
nausea/vomiting (grade I/II)	0.76	sd: 0.28	No comparison state (anchored to 1 for chemotherapy patient)	-	-	TTO	Public: women (n=37)	Havrilesky et al (2009)
nausea/vomiting (grade III/IV)	0.60	sd: 0.40	No comparison state (anchored to 1 for chemotherapy patient)	-	-	TTO	Patients: women (n=13)	Havrilesky et al (2009)
nausea/vomiting (grade III/IV)	0.63	sd: 0.30	No comparison state (anchored to 1 for chemotherapy patient)	-	-	TTO	Public: women (n=37)	Havrilesky et al (2009)
nausea/vomiting (grade III/IV) (with stoma)	Simple mean = 0.34 estimated mean = 0.34	CI for estimated mean:0.30 to 0.37	'Dummy' health states for metastatic cancer on chemotherapy (no description of ADEs, with stoma)	Simple mean = 0.42 estimated mean = 0.43	CI for estimated mean :0.40 - 0.46	SG	Public: ADE state (n=177) Comparison state (n= 201)	Shiroiwa et al (2009)
nausea/vomiting (grade III/IV) (with stoma)	Simple mean = 0.34 estimated mean = 0.34	CI for estimated mean:0.31 to 0.38	'Dummy' health states for metastatic cancer on chemotherapy (no description of ADEs, with stoma)	Simple mean = 0.42 Estimated mean = 0.43	(CI for estimated mean: 0.40 - 0.47)	TTO	Public: ADE state (n=177) Comparison state (n= 201)	Shiroiwa et al (2009)
nausea/vomiting (grade III/IV) (without stoma)	Simple mean = 0.37 estimated mean = 0.39	CI for estimated mean:0.35 to 0.42	'Dummy' health states for metastatic cancer on chemotherapy (no description of ADEs, without stoma)	Simple mean = 0.44 estimated mean = 0.48	CI for estimated mean:0.44 to 0.51	SG	Public: ADE state (n=192) Comparison state (n= 168)	Shiroiwa et al (2009)
nausea/vomiting (grade III/IV) (without stoma)	Simple mean = 0.36 estimated mean = 0.38	CI for estimated mean: 0.35 to 0.42	'Dummy' health states for metastatic cancer on chemotherapy (no description of ADEs, without stoma)	Simple mean = 0.44 estimated mean = 0.47	CI for estimated mean: 0.44 to 0.51	TTO	Public: ADE state (n=192) Comparison state (n= 168)	Shiroiwa et al (2009)
Neuropathy (21 values)	Mean utility value for adverse event	Variation around mean	Base state/Comparison state	Mean utility for comparison state	Variation around mean	Valua-tion method	Study sample (n)	Study (year)
mild neuropathy	0.57 (raw)	Not reported	Adjuvant chemotherapy	0.64 (raw)	Not reported	TTO	Patients (n=49) & Public (n=49)	Best et al (2010)
mild neuropathy	0.65 (raw)	Not reported	Adjuvant	0.67 (raw)	Not	TTO	Patients (n=49)	Best et al

Appendix 3: Utility values for chemotherapy-related adverse events

	0.61 (adjusted)		chemotherapy	0.61 (adjusted)	reported			(2010)
mild neuropathy	0.52 (raw) 0.51 (adjusted)	Not reported	Adjuvant chemotherapy	0.62 (raw) 0.60 (adjusted)	Not reported	TTO	Public (n=49)	Best et al (2010)
moderate neuropathy	0.51 (raw)	Not reported	Adjuvant chemotherapy	0.64 (raw)	Not reported	TTO	Patients (n=49) & Public (n=49)	Best et al (2010)
moderate neuropathy	0.55 (raw) 0.53 (adjusted)	Not reported	Adjuvant chemotherapy	0.67 (raw) 0.61 (adjusted)	Not reported	TTO	Patients (n=49)	Best et al (2010)
moderate neuropathy	0.48 (raw) 0.46 (adjusted)	Not reported	Adjuvant chemotherapy	0.62 (raw) 0.60 (adjusted)	Not reported	TTO	Public (n=49)	Best et al (2010)
severe neuropathy	0.40 (raw)	Not reported	Adjuvant chemotherapy	0.64 (raw)	Not reported	TTO	Patients (n=49) & Public (n=49)	Best et al (2010)
severe neuropathy	0.48 (raw) 0.48 (adjusted)	Not reported	Adjuvant chemotherapy	0.67 (raw) 0.61 (adjusted)	Not reported	TTO	Patients (n=49)	Best et al (2010)
severe neuropathy	0.35 (raw) 0.34 (adjusted)	Not reported	Adjuvant chemotherapy	0.62 (raw) 0.60 (adjusted)	Not reported	TTO	Public (n=49)	Best et al (2010)
peripheral neuropathy with partial/complete response	0.62	sd: 0.16	partial/complete response	0.84	sd: 0.12	SG	UK oncology nurses (n=30) [c]	Brown et al (2001)
peripheral neuropathy with partial response	0.53	Not reported	partial response	0.81	Not reported	SG	Oncology nurses (n=129)	Hutton et al (1996)
peripheral neuropathy (grade I/II)	0.95	sd: 0.04	No comparison state	-	-	TTO	Patients: women (n=13)	Havrilesky et al (2009)
peripheral neuropathy (grade I/II)	0.81	sd: 0.29	No comparison state	-	-	TTO	Public: women (n=37)	Havrilesky et al (2009)
peripheral neuropathy (grade III/IV)	0.73	sd: 0.27	No comparison state	-	-	TTO	Patients: women (n=13)	Havrilesky et al (2009)
peripheral neuropathy (grade III/IV)	0.65	sd: 0.31	No comparison state	-	-	TTO	Public: women (n=37)	Havrilesky et al (2009)
peripheral neuropathy	0.94	se: 0.02	Untreated cancer	0.92	se: 0.03	SG	HCPs: men (n=24)	Nguyen et al (2010)
peripheral neuropathy	0.55	se: 0.06	Untreated cancer	0.49	se: 0.06	VAS	HCPs: men (n=24)	Nguyen et al (2010)
peripheral neuropathy grade III/IV (with stoma)	simple mean = 0.41 estimated mean = 0.40	CI for estimated mean: 0.36 to 0.43	'Dummy' health states for metastatic cancer on chemotherapy (no description of ADEs, with stoma)	Simple mean = 0.42 estimated mean = 0.43	CI for estimated mean :0.40 to 0.46	SG	Public: ADE state (n=179) Comparison state (n= 201)	Shiroiwa et al (2009)
peripheral neuropathy grade III/IV (with	simple mean =0.43 estimated mean = 0. 41	CI for estimated	'Dummy' health states for metastatic cancer	Simple mean = 0.42 estimated mean = 0.43	CI for estimate	TTO	Public: ADE state	Shiroiwa et

Appendix 3: Utility values for chemotherapy-related adverse events

stoma)		mean: 0.37 to 0.44	on chemotherapy (no description of ADEs, with stoma)		d mean: 0.40 to 0.47		(n=179) Comparison state (n= 201)	al (2009)
peripheral neuropathy grade III/IV (without stoma)	simple mean =0.41 estimated mean = 0.44	CI for estimated mean: 0.41 to 0.48	'Dummy' health states for metastatic cancer on chemotherapy (no description of ADEs, without stoma)	Simple mean = 0.44 estimated mean = 0.48	CI for estimated mean:0.44 to 0.51	SG	Public: ADE state (n=176) Comparison state (n= 168)	Shiroiwa et al (2009)
peripheral neuropathy grade III/IV (without stoma)	simple mean =0.42 estimated mean = 0.45	CI for estimated mean: 0.41 to 0.48	'Dummy' health states for metastatic cancer on chemotherapy (no description of ADEs, without stoma)	Simple mean = 0.44 estimated mean = 0.47	CI for estimated mean: 0.44 to 0.51	TTO	Public: ADE state (n=176) Comparison state (n= 168)	Shiroiwa et al (2009)
Neutropaenia (12 values)	Mean utility value for adverse event	Variation around mean	Base state/Comparison state	Mean utility for comparison state	Variation around mean	Valua-tion method	Study sample (n)	Study (year)
febrile neutropaenia	Utility decrement - 0.150	Not reported	Stable disease with no toxicity	0.715	Not reported	SG	Public (n=100)	Lloyd et al (2006)
neutropaenia	Utility decrement -0.08973	se: 0.01543	Stable disease with no toxicity	0.653	se: 0.02223	SG	Public (n=100)	Nafees et al (2008)
febrile neutropaenia	Utility decrement -0.09002	se: 0.01633	Stable disease with no toxicity	0.653	se: 0.02223	SG	Public (n=100)	Nafees et al (2008)
febrile neutropaenia and hospitalised	0.24	sd: 0.12	No comparison state	-	-	SG	UK oncology nurses (n=30) [c]	Brown et al (2001)
neutropaenia (grade IV)	0.70	sd: 0.30	No comparison state	-	-	TTO	Patients: women (n=13)	Havrilesky et al (2009)
neutropaenia (grade IV)	0.64	sd: 0.36	No comparison state	-	-	TTO	Public: women (n=37)	Havrilesky et al (2009)
febrile neutropaenia	0.54	sd: 0.15	No comparison state	-	-	TTO	Patients: women (n=13)	Havrilesky et al (2009)
febrile neutropaenia	0.56	sd: 0.34	No comparison state	-	-	TTO	Public: women (n=37)	Havrilesky et al (2009)
febrile neutropaenia with stoma	Simple mean = 0.38 estimated mean = 0.39	CI for estimated mean: 0.35 – 0.42	'Dummy' health states for metastatic cancer on chemotherapy (no description of ADEs, with stoma)	Simple mean = 0.42 estimated mean = 0.43	CI for estimated mean :0.40 to 0.46	SG	Public: ADE state (n=196) Comparison state (n= 201)	Shiroiwa et al (2009)
febrile neutropaenia with stoma	Simple mean = 0.36 estimated mean = 0.35	CI for estimated	'Dummy' health states for metastatic cancer	Simple mean = 0.42 estimated mean = 0. 43	CI for estimate	TTO	Public: ADE state	Shiroiwa et al (2009)

Appendix 3: Utility values for chemotherapy-related adverse events

		mean: 0.32 – 0.38	on chemotherapy (no description of ADEs, with stoma)		d mean: 0.40 to 0.47		(n=196) Comparison state (n= 201)	
febrile neutropaenia without stoma	Simple mean = 0.48 estimated mean = 0.43	CI for estimated mean: 0.40 – 0.47	'Dummy' health states for metastatic cancer on chemotherapy (no description of ADEs, without stoma)	Simple mean = 0.44 estimated mean = 0.48	CI for estimated mean:0.44 - 0.51	SG	Public: ADE state (n=175) Comparison state (n= 168)	Shiroiwa et al (2009)
febrile neutropaenia without stoma	Simple mean = 0.41 estimated mean = 0.39	CI for estimated mean: 0.36 – 0.42	'Dummy' health states for metastatic cancer on chemotherapy (no description of ADEs, without stoma)	Simple mean = 0.44 estimated mean = 0.47	CI for estimated mean: 0.44 - 0.51	TTO	Public: ADE state (n=175) Comparison state (n= 168)	Shiroiwa et al (2009)
Anaemia (34 values)	Mean utility value for adverse event	Variation around mean	Base state/Comparison state	Mean utility for comparison state	Variation around mean	Valua-tion method	Study sample (n)	Study (year)
Anemia (grade III/IV)	0.69	sd: 0.18	No Change (NC)	0.78	sd: 0.14	SG	Public: England (n=59) Scotland (n=30)	Beusterien et al (2010)[b]
Anemia (grade III/IV)	0.66	sd: 0.19	No Change (NC)	0.76	sd: 0.15	SG	Public: England (n=59)	Beusterien et al (2010)[b]
Anemia (grade III/IV)	0.74	sd: 0.17	No Change (NC)	0.83	sd: 0.11	SG	Public: Scotland (n=30)	Beusterien et al (2010)[b]
Anemia 7.0–8.0 g/dL	0.583	CI: 0.067	No comparison state	-	-	SG	Public (n=83)	Lloyd et al (2008)
Anemia 7.0–8.0 g/dL	0.169	CI: 0.026	No comparison state	-	-	VAS	Public (n=83)	Lloyd et al (2008)
Anemia 7.0–8.0 g/dL	0.297	CI: 0.127	No comparison state	-	-	TTO	Patients (n=26)	Lloyd et al (2008)
Anemia 7.0–8.0 g/dL	0.217	CI: 0.057	No comparison state	-	-	VAS	Patients (n=26)	Lloyd et al (2008)
Anemia 8.0–9.0 g/dL	0.608	CI: 0.064	No comparison state	-	-	SG	Public (n=83)	Lloyd et al (2008)
Anemia 8.0–9.0 g/dL	0.223	CI: 0.030	No comparison state	-	-	VAS	Public (n=83)	Lloyd et al (2008)
Anemia 8.0–9.0 g/dL	0.360	CI: 0.126	No comparison state	-	-	TTO	Patients (n=26)	Lloyd et al (2008)
Anemia	0.324	CI: 0.066	No comparison state	-	-	VAS	Patients (n=26)	Lloyd et al

Appendix 3: Utility values for chemotherapy-related adverse events

8.0–9.0 g/dL								(2008)
Anemia 9.0–10.0 g/dL	0.640	CI: 0.060	No comparison state	-	-	SG	Public (n=83)	Lloyd et al (2008)
Anemia 9.0–10.0 g/dL	0.276	CI: 0.029	No comparison state	-	-	VAS	Public (n=83)	Lloyd et al (2008)
Anemia 9.0–10.0 g/dL	0.408	CI: 0.125	No comparison state	-	-	TTO	Patients (n=26)	Lloyd et al (2008)
Anemia 9.0–10.0 g/dL	0.342	CI: 0.067	No comparison state	-	-	VAS	Patients (n=26)	Lloyd et al (2008)
Anemia 10.0–10.5 g/dL	0.642	CI: 0.062	No comparison state	-	-	SG	Public (n=83)	Lloyd et al (2008)
Anemia 10.0–10.5 g/dL	0.329	CI: 0.034	No comparison state	-	-	VAS	Public (n=83)	Lloyd et al (2008)
Anemia 10.0–10.5 g/dL	0.446	CI: 0.122	No comparison state	-	-	TTO	Patients (n=26)	Lloyd et al (2008)
Anemia 10.0–10.5 g/dL	0.419	CI: 0.066	No comparison state	-	-	VAS	Patients (n=26)	Lloyd et al (2008)
Anemia 10.5–11.0 g/dL	0.661	CI: 0.061	No comparison state	-	-	SG	Public (n=83)	Lloyd et al (2008)
Anemia 10.5–11.0 g/dL	0.388	CI: 0.036	No comparison state	-	-	VAS	Public (n=83)	Lloyd et al (2008)
Anemia 10.5–11.0 g/dL	0.454	CI: 0.111	No comparison state	-	-	TTO	Patients (n=26)	Lloyd et al (2008)
Anemia 10.5–11.0 g/dL	0.447	CI: 0.066	No comparison state	-	-	VAS	Patients (n=26)	Lloyd et al (2008)
Anemia 11.0–12.0 g/dL	0.703	CI: 0.056	No comparison state	-	-	SG	Public (n=83)	Lloyd et al (2008)
Anemia 11.0–12.0 g/dL	0.459	CI: 0.042	No comparison state	-	-	VAS	Public (n=83)	Lloyd et al (2008)
Anemia 11.0–12.0 g/dL	0.545	CI: 0.105	No comparison state	-	-	TTO	Patients (n=26)	Lloyd et al (2008)
Anemia 11.0–12.0 g/dL	0.522	CI: 0.068	No comparison state	-	-	VAS	Patients (n=26)	Lloyd et al (2008)
Anemia 12.0+ g/dL	0.708	CI: 0.057	No comparison state	-	-	SG	Public (n=83)	Lloyd et al (2008)
Anemia 12.0+ g/dL	0.512	CI: 0.043	No comparison state	-	-	VAS	Public (n=83)	Lloyd et al (2008)
Anemia 12.0+ g/dL	0.611	CI: 0.112	No comparison state	-	-	TTO	Patients (n=26)	Lloyd et al (2008)

Appendix 3: Utility values for chemotherapy-related adverse events

Anemia 12.0+ g/dL	0.624	CI: 0.079	No comparison state	-	-	VAS	Patients (n=26)	Lloyd et al (2008)
Mild anaemia (Hb: 10.2g/dl)	0.78	sd: 0.17, se: 0.016	No anaemia (Hb:11g/dl)	0.86	sd: 0.14, se: 0.014	TTO	Public (n=106)	Ossa et al (2007)
Moderate anaemia (Hb: 8.7g/dl)	0.61	sd: 0.21, se: 0.020	No anaemia (Hb:11g/dl)	0.86	sd: 0.14, se: 0.014	TTO	Public (n=106)	Ossa et al (2007)
Severe anaemia (Hb: 7.2g/dl)	0.48	sd: 0.21, se: 0.020	No anaemia (Hb:11g/dl)	0.86	sd: 0.14, se: 0.014	TTO	Public (n=106)	Ossa et al (2007)
Alopecia (7 values)	Mean utility value for adverse event	Variation around mean	Base state/Comparison state	Mean utility for comparison state	Variation around mean	Valua-tion method	Study sample (n)	Study (year)
Hair loss (grade I/II)	Utility decrement -0.03	se: 0.01	Partial response	0.88	se: 0.01	SG	Public: UK (n=63) & Australian (n=77)	Beusterien et al (2009)
Hair loss (grade I/II)	Utility decrement -0.03	se: 0.01	Partial response	0.85	se: 0.01	SG	Public: UK (n=63)	Beusterien et al (2009)
Hair loss (grade I/II)	Utility decrement -0.03	se: 0.01	Partial response	0.91	se: 0.01	SG	Public:Australian (n=77)	Beusterien et al (2009)
Hair loss	Utility decrement - 0.114	Not reported	Stable disease with no toxicity	0.715	Not reported	SG	Public (n=100)	Lloyd et al (2006)
Hair loss	Utility decrement -0.04495	se: 0.01482	Stable disease with no toxicity	0.653	0.02223	SG	Public (n=100)	Nafees et al (2008)
Alopecia (grade II)	0.90	sd: 0.15	No comparison state	-	-	TTO	Patients: women (n=13)	Havrilesky et al (2009)
Alopecia (grade II)	0.84	sd: 0.29	No comparison state	-	-	TTO	Public: women (n=37)	Havrilesky et al (2009)
Skin reaction (5 values)	Mean utility value for adverse event	Variation around mean	Base state/Comparison state	Mean utility for comparison state	Variation around mean	Valua-tion method	Study sample (n)	Study (year)
Skin reaction (grade I/II)	Utility decrement -0.06	se: 0.01	Partial response	0.88	se: 0.01	SG	Public: UK (n=63) & Australian(n=77)	Beusterien et al (2009)
Skin reaction (grade I/II)	Utility decrement -0.03	se: 0.01	Partial response	0.85	se: 0.01	SG	Public: UK (n=63)	Beusterien et al (2009)
Skin reaction (grade I/II)	Utility decrement -0.08	se: 0.01	Partial response	0.91	se: 0.01	SG	Public: Australian (n=77)	Beusterien et al (2009)
Rash	Utility decrement	se: 0.01171	Stable disease with no	= 0.653	0.02223	SG	Public (n=100)	Nafees et al

Appendix 3: Utility values for chemotherapy-related adverse events

	-0.03248		toxicity					(2008)
Severe skin condition with partial/complete response	0.56	no sd (utility estimated from other ADEs)	Partial/complete response	0.84	sd: 0.12	SG	UK oncology nurses (n=30) [c]	Brown et al (2001)
Hand-foot syndrome (5 values)	Mean utility value for adverse event	Variation around mean	Base state/Comparison state	Mean utility for comparison state	Variation around mean	Valua-tion method	Study sample (n)	Study (year)
Hand-foot syndrome	Utility decrement - 0.116	Not reported	Stable disease with no toxicity	0.715	Not reported	SG	Public (n=100)	Lloyd et al (2006)
Hand and foot syndrome grade III/IV with stoma	Simple mean = = 0.36 estimated mean = 0.35	CI for estimated mean: 0.31 to 0.38	'Dummy' health states for metastatic cancer on unspecified chemotherapy (no description of ADEs, with stoma)	Simple mean = 0.42 estimated mean = 0.43	CI for estimate d mean :0.40 to 0.46	SG	Public: ADE state (n=189) Comparison state (n= 201)	Shiroiwa et al (2009)
Hand and foot syndrome grade III/IV with stoma	Simple mean = = 0.36 estimated mean = 0.35	CI for estimated mean: 0.32 to 0.38	'Dummy' health states for metastatic cancer on unspecified chemotherapy (no description of ADEs, with stoma)	Simple mean = 0.42 estimated mean = 0.43	CI for estimate d mean: 0.40 to 0.47	TTO	Public: ADE state (n=189) Comparison state (n= 201)	Shiroiwa et al (2009)
Hand and foot syndrome grade III/IV without stoma	Simple mean = = 0.34 estimated mean = 0.39	CI for estimated mean: 0.36 to 0.43	'Dummy' health states for metastatic cancer on chemotherapy (no description of ADEs, without stoma)	Simple mean = 0.44 estimated mean = 0.48	CI for estimate d mean:0.4 4 to 0.51	SG	Public: ADE state (n=174) Comparison state (n= 168)	Shiroiwa et al (2009)
Hand and foot syndrome grade III/IV without stoma	Simple mean = = 0.38 estimated mean = 0.39	CI for estimated mean: 0.36 to 0.42	'Dummy' health states for metastatic cancer on chemotherapy (no description of ADEs, without stoma)	Simple mean = 0.44 estimated mean = 0.47	CI for estimate d mean: 0.44 to 0.51	TTO	Public: ADE state (n=174) Comparison state (n= 168)	Shiroiwa et al (2009)
Fatigue (8 values)	Mean utility value for adverse event	Variation around mean	Base state/Comparison state	Mean utility for comparison state	Variation around mean	Valua-tion method	Study sample (n)	Study (year)
Fatigue	Utility decrement - 0.115	Not reported	Stable disease with no toxicity	= 0.715	Not reported	SG	Public (n=100)	Lloyd et al (2006)
Fatigue	Utility decrement -0.07346	se: 0.01849	Stable disease with no toxicity	= 0.653	0.02223	SG	Public (n=100)	Nafees et al (2008)

Appendix 3: Utility values for chemotherapy-related adverse events

Fatigue (grade III/IV)	0.66 for patients	sd: 0.35	No comparison state	-	-	TTO	Patients: women (n=13)	Havrilesky et al (2009)
Fatigue (grade III/IV)	0.58 for public	sd: 0.33	No comparison state	-	-	TTO	Public: women (n=37)	Havrilesky et al (2009)
Fatigue grade III/IV with stoma	Simple mean = 0.40 estimated mean = 0.38	CI for estimated mean: 0.35 to 0.42	'Dummy' health states for metastatic cancer on chemotherapy (no description of ADEs, with stoma)	Simple mean = 0.42 estimated mean = 0.43	CI for estimated mean :0.40 to 0.46	SG	Public: ADE state (n=186) Comparison state (n= 201)	Shiroiwa et al (2009)
Fatigue grade III/IV with stoma	Simple mean = 0.40 estimated mean = 0.41	CI for estimated mean: 0.37 to 0.44)	'Dummy' health states for metastatic cancer on chemotherapy (no description of ADEs, with stoma)	Simple mean = 0.42 estimated mean = 0. 43	CI for estimated mean: 0.40 to 0.47	TTO	Public: ADE state (n=186) Comparison state (n= 201)	Shiroiwa et al (2009)
Fatigue grade III/IV without stoma	Simple mean = 0.43 estimated mean = 0.43	(CI for estimated mean: 0.39 to 0.46)	'Dummy' health states for metastatic cancer on chemotherapy (no description of ADEs, without stoma)	Simple mean = 0.44 estimated mean = 0.48	CI for estimated mean:0.44 to 0.51	SG	Public: ADE state (n=185) Comparison state (n= 168)	Shiroiwa et al (2009)
Fatigue grade III/IV without stoma	Simple mean = 0.46 estimated mean = 0.45	(CI for estimated mean: 0.41 to 0.48)	'Dummy' health states for metastatic cancer on chemotherapy (no description of ADEs, without stoma)	Simple mean = 0.44 estimated mean = 0.47	CI for estimated mean: 0.44 to 0.51	TTO	Public: ADE state (n=185) Comparison state (n= 168)	Shiroiwa et al (2009)
Diarrhoea (12 values)	Mean utility value for adverse event	Variation around mean	Base state/Comparison state	Mean utility for comparison state	Variation around mean	Valua-tion method	Study sample (n)	Study (year)
Diarrhoea (grade I/II)	Utility decrement -0.09	se: 0.01	Base state: Partial response	0.88	se: 0.01	SG	Public: Australian (n=77) UK (n=63)	Beusterien et al (2009)
Diarrhoea (grade I/II)	Utility decrement -0.06	se: 0.01	Base state: Partial response	0.85	se: 0.01	SG	Public: UK (n=63)	Beusterien et al (2009)
Diarrhoea (grade I/II)	Utility decrement -0.11	se: 0.01	Base state: Partial response	0.91	se: 0.01	SG	Public:Australian (n=77)	Beusterien et al (2009)
Diarrhoea	Utility decrement -0.04680	se: 0.01553	Base state: stable disease with no toxicity	0.653	0.02223	SG	Public (n=100)	Nafees et al (2008)
Diarrhoea and vomiting	Utility decrement -0.103	Not reported	Stable disease with no toxicity	0.715	Not reported	SG	Public (n=100)	Lloyd et al (2006)

Appendix 3: Utility values for chemotherapy-related adverse events

Diarrhoea (grade I/II)	0.70	sd: 0.19	No Change	0. 78	sd: 0.14	SG	Public: England (n=59) Scotland n=30)	Beusterien et al (2010)[b]
Diarrhoea (grade I/II)	0.68	sd: 0.19	No Change	0. 76	sd: 0.15	SG	Public: England (n=59)	Beusterien et al (2010)[b]
Diarrhoea (grade I/II)	0.75	sd: 0.17	No Change	0. 83	sd: 0.11	SG	Public: Scotland n=30)	Beusterien et al (2010)[b]
Diarrhoea grade III/IV with stoma	Simple mean = 0.40 estimated mean = 0.37	CI for estimated mean:0.34 to 0.41	'Dummy' health states for metastatic cancer on chemotherapy (no description of ADEs, with stoma)	Simple mean = 0.42 estimated mean = 0.43	CI for estimated mean :0.40 to 0.46	SG	Public: ADE state (n=170) Comparison state (n= 201)	Shiroiwa et al (2009)
Diarrhoea grade III/IV with stoma	Simple mean = 0.43 estimated mean = 0.38	CI for estimated mean: 0.35 to 0.41	'Dummy' health states for metastatic cancer on chemotherapy (no description of ADEs, with stoma)	Simple mean = 0.42 estimated mean = 0.43	CI for estimated mean: 0.40 to 0.47	TTO	Public: ADE state (n=170) Comparison state (n= 201)	Shiroiwa et al (2009)
Diarrhoea grade III/IV without stoma	Simple mean = 0.37 estimated mean = 0.42	CI for estimated mean: 0.39 to 0.46	'Dummy' health states for metastatic cancer on chemotherapy (no description of ADEs, without stoma)	Simple mean = 0.44 estimated mean = 0.48	CI for estimated mean:0.44 to 0.51	SG	Public: ADE state (n=188) Comparison state (n= 168)	Shiroiwa et al (2009)
Diarrhoea grade III/IV without stoma	Simple mean = 0.36 estimated mean = 0.42	CI for estimated mean: 0.39 to 0.45	'Dummy' health states for metastatic cancer on chemotherapy (no description of ADEs, without stoma)	Simple mean = 0.44 estimated mean = 0.47	CI for estimated mean: 0.44 to 0.51	TTO	Public: ADE state (n=188) Comparison state (n= 168)	Shiroiwa et al (2009)
Stomatitis (10 values)	Mean utility value for adverse event	Variation around mean	Base state/Comparison state	Mean utility for comparison state	Variation around mean	Valua-tion method	Study sample (n)	Study (year)
Stomatitis (grade I/II)	Utility decrement -0.13 for all sample	se: 0.01	Base state: Partial response	0.88	se: 0.01	SG	Public: Australian (n=77) UK (n=63)	Beusterien et al (2009)
Stomatitis (grade I/II)	Utility decrement -0.10 for UK sample	se: 0.01	Base state: Partial response	0.85	se: 0.01	SG	Public: UK (n=63)	Beusterien et al (2009)
Stomatitis (grade I/II)	Utility decrement -0.14	se: 0.01	Base state: Partial response	0.91	se: 0.01	SG	Public: Australian(n=77)	Beusterien et al (2009)
Stomatitis	Utility decrement	Not reported	Stable disease with no	0.715	Not	SG	Public (n=100)	Lloyd et al

Appendix 3: Utility values for chemotherapy-related adverse events

	- 0.151		toxicity		reported			(2006)
Stomatitis (grade II)	0.88	sd: 0.15	No comparison state	-	-	TTO	Patients: women (n=13)	Havrilesky et al (2009)
Stomatitis (grade II)	0.91	sd: 0.08	No comparison state	-	-	TTO	Public: women (n=37)	Havrilesky et al (2009)
Stomatitis grade III/IV with stoma	Simple mean = 0.40 estimated mean = 0.40	(CI for estimated mean: 0.36 to 0.43)	'Dummy' health states for metastatic cancer on chemotherapy (no description of ADEs, with stoma)	Simple mean = 0.42 estimated mean = 0.43	CI for estimated mean :0.40 to 0.46	SG	Public: ADE state (n=167) Comparison state (n= 201)	Shiroiwa et al (2009)
Stomatitis grade III/IV with stoma	Simple mean = 0.38 estimated mean = 0.38	(CI for estimated mean: 0.34 to 0.41)	'Dummy' health states for metastatic cancer on chemotherapy (no description of ADEs, with stoma)	Simple mean = 0.42 estimated mean = 0.43	CI for estimated mean: 0.40 to 0.47	TTO	Public: ADE state (n=167) Comparison state (n= 201)	Shiroiwa et al (2009)
Stomatitis grade III/IV without stoma	Simple mean = 0.43 estimated mean =0.44	(CI for estimated mean: 0.41 to 0.48)	'Dummy' health states for metastatic cancer on chemotherapy (no description of ADEs, without stoma)	Simple mean = 0.44 estimated mean = 0.48	CI for estimated mean:0.44 to 0.51	SG	Public: ADE state (n=202) Comparison state (n= 168)	Shiroiwa et al (2009)
Stomatitis grade III/IV without stoma	Simple mean = 0.40 estimated mean = 0.42	(CI for estimated mean: 0.39 to 0.45)	'Dummy' health states for metastatic cancer on chemotherapy (no description of ADEs, without stoma)	Simple mean = 0.44 estimated mean = 0.47	CI for estimated mean: 0.44 to 0.51	TTO	Public: ADE state (n=202) Comparison state (n= 168)	Shiroiwa et al (2009)
Secondary cancers (2 values)	Mean utility value for adverse event	Variation around mean	Base state/Comparison state	Mean utility for comparison state	Variation around mean	Valua-tion method	Study sample (n)	Study (year)
Secondary malignant neoplasms	0.77	se: 0.05	Untreated cancer	0.92	se: 0.03	SG	HCPs: men (n=24)	Nguyen et al (2010)
Secondary malignant neoplasms	0.29	se: 0.05	Untreated cancer	0.49	se: 0.06	VAS	HCPs: men (n=24)	Nguyen et al (2010)
Pyrexia (3 values)	Mean utility value for adverse event	Variation around mean	Base state/Comparison state	Mean utility for comparison state	Variation around mean	Valua-tion method	Study sample (n)	Study (year)
Pyrexia (grade III/IV)	0.67	sd: 0.17	No Change	0. 78	sd: 0.14	SG	Public: England (n=59) Scotland (n=30)	Beusterien et al (2010)[b]
Pyrexia (grade III/IV)	0.64	sd: 0.17	No Change	0. 76	sd: 0.15	SG	Public:	Beusterien

Appendix 3: Utility values for chemotherapy-related adverse events

							England (n=59)	et al (2010)[b]
Pyrexia (grade III/IV)	0.72	sd: 0.17	No Change	0. 83	sd: 0.11	SG	Public: Scotland (n=30)	Beusterien et al (2010)[b]
Cardiovascular disease (2 values)	Mean utility value for adverse event	Variation around mean	Base state/Comparison state	Mean utility for comparison state	Variation around mean	Valua-tion method	Study sample (n)	Study (year)
Cardiovascular disease	0.91	se: 0.02	Untreated cancer	0.92	se: 0.03	SG	HCPs: men (n=24)	Nguyen et al (2010)
Cardiovascular disease	0.43	se: 0.04	Untreated cancer	0.49	se: 0.06	VAS	HCPs: men (n=24)	Nguyen et al (2010)
Ototoxicity (2 values)	Mean utility value for adverse event	Variation around mean	Base state/Comparison state	Mean utility for comparison state	Variation around mean	Valua-tion method	Study sample (n)	Study (year)
Ototoxicity	0.96	se: 0.02	Untreated cancer	0.92	se: 0.03	SG	HCPs: men (n=24)	Nguyen et al (2010)
Ototoxicity	0.68	se: 0.05	Untreated cancer	0.49	se: 0.06	VAS	HCPs: men (n=24)	Nguyen et al (2010)
Flu-like syndrome (3 values)	Mean utility value for adverse event	Variation around mean	Base state/Comparison state	Mean utility for comparison state	Variation around mean	Valua-tion method	Study sample (n)	Study (year)
Flu-like syndrome (grade I/II)	Utility decrement -0.11	se: 0.01	Base state: Partial response	0.88	se: 0.01	SG	Public: Australian (n=77) UK (n=63)	Beusterien et al (2009)
Flu-like syndrome (grade I/II)	Utility decrement -0.09	se: 0.01	Base state: Partial response	0.85	se: 0.01	SG	Public: UK (n=63)	Beusterien et al (2009)
Flu-like syndrome (grade I/II)	Utility decrement -0.13	se: 0.01	Base state: Partial response	0.91	se: 0.01	SG	Public: Australian(n=77)	Beusterien et al (2009)
Oedema (2 values)	Mean utility value for adverse event	Variation around mean	Base state/Comparison state	Mean utility for comparison state	Variation around mean	Valua-tion method	Study sample (n)	Study (year)
Severe oedema with partial/complete response	0.78	sd: 0.15	partial/complete response	0.84	sd: 0.12	SG	UK oncology nurses (n=30) [c]	Brown et al (2001)
Severe peripheral oedema with partial response	0.75	Not reported	partial response	0.81	Not reported	SG	Oncology nurses (n=129)	Hutton et al (1996)

Appendix 3: Utility values for chemotherapy-related adverse events

Infection-related events (5 values)	Mean utility value for adverse event	Variation around mean	Base state/Comparison state	Mean utility for comparison state	Variation around mean	Valua-tion method	Study sample (n)	Study (year)
Pneumonia (grade III/IV)	0.58	sd: 0.19	No Change	0. 78	sd: 0.14	SG	Public: England (n=59) Scotland (n=30)	Beusterien et al (2010)[b]
Pneumonia (grade III/IV)	0.56	sd: 0.20	No Change	0. 76	sd: 0.15	SG	Public: England (n=59)	Beusterien et al (2010)[b]
Pneumonia (grade III/IV)	0.63	sd:0.19	No Change	0. 83	sd: 0.11	SG	Public: Scotland (n=30)	Beusterien et al (2010)[a]
Infection without hospitalisation	0.48	Not reported	No comparison state	-	-	SG	UK oncology nurses (n=30) [c]	Brown et al (2001)
Sepsis	0.20	Not reported	No comparison state	-	-	SG	Oncology nurses (n=129)	Hutton et al (1996)
Myalgia pain (4 values)	Mean utility value for adverse event	Variation around mean	Base state/Comparison state	Mean utility for comparison state	Variation around mean	Valua-tion method	Study sample (n)	Study (year)
Myalgia pain (grade I/II)	0.86	sd: 0.15	No comparison state	-	-	TTO	Patients: women (n=13)	Havrilesky et al (2009)
Myalgia pain (grade I/II)	0.89	sd: 0.12	No comparison state	-	-	TTO	Public: women (n=37)	Havrilesky et al (2009)
Myalgia pain (grade III/IV)	0.72	sd: 0.30	No comparison state	-	-	TTO	Patients: women (n=13)	Havrilesky et al (2009)
Myalgia pain (grade III/IV)	0.46	sd: 0.39	No comparison state	-	-	TTO	Public: women (n=37)	Havrilesky et al (2009)
Common adverse events specific to a chemotherapy drug (6 values)	Mean utility value for adverse event	Variation around mean	Base state/Comparison state	Mean utility for comparison state	Variation around mean	Valua-tion method	Study sample (n)	Study (year)
Toxicity from treatment (Paclitaxel)	0.12	Not reported	No comparison state	-	-	TTO	Public: women (n=25)	Leung et al (1999)
Toxicity from treatment (Paclitaxel)	0.11	Not reported	No comparison state	-	-	TTO	Patients: women (n=25)	Leung et al (1999)
Toxicity from treatment (docetaxel)	0.1	Not reported	No comparison state	-	-	TTO	Public: women (n=25)	Leung et al (1999)
Toxicity from treatment (docetaxel)	0.09	Not reported	No comparison state	-	-	TTO	Patients: women (n=25)	Leung et al (1999)
Toxicity from treatment	0.23	Not reported	No comparison state	-	-	TTO	Public: women (n=25)	Leung et al (1999)

Appendix 3: Utility values for chemotherapy-related adverse events

(vinorelbine)								
Toxicity from treatment (vinorelbine)	0.16	Not reported	No comparison state	-	-	TTO	Patients: women (n=25)	Leung et al (1999)
Adverse events leading to hospital stay (6 values)	Mean utility value for adverse event	Variation around mean	Base state/Comparison state	Mean utility for comparison state	Variation around mean	Valua-tion method	Study sample (n)	Study (year)
One-day inpatient or outpatient stay for severe toxicity (grade III/IV)	Utility decrement -0.13	se: 0.01	Base state: Partial response	0.88	se: 0.01	SG	Public: Australian (n=77) UK (n=63)	Beusterien et al (2009)
One-day in or outpatient stay for severe toxicity (grade III/IV)	Utility decrement -0.11	se: 0.01	Base state: Partial response	0.85	se: 0.01	SG	Public: UK (n=63)	Beusterien et al (2009)
One-day in or outpatient stay for severe toxicity (grade III/IV)	Utility decrement -0.14	se: 0.01	Base state: Partial response	0.91	se: 0.01	SG	Public: Australian (n=77)	Beusterien et al (2009)
Hospitalisation (2-5 days) for severe toxicity (grade III/IV)	Utility decrement -0.17	se: 0.01	Base state: Partial response	0.88	se: 0.01	SG	Public: Australian (n=77), UK(n=63)	Beusterien et al (2009)
Hospitalisation (2-5 days) for severe toxicity (grade III/IV)	Utility decrement -0.13	se: 0.01	Base state: Partial response	0.85	se: 0.01	SG	Public: UK (n=63)	Beusterien et al (2009)
Hospitalisation (2-5 days) for severe toxicity (grade III/IV)	Utility decrement -0.20	se: 0.01	Base state: Partial response	0.91	se: 0.01	SG	Public: Australian (n=77)	Beusterien et al (2009)
Non-specific events relating to ADEs (37 values)	Mean utility value for adverse event	Variation around mean	Base state/Comparison state	Mean utility for comparison state	Variation around mean	Valua-tion method	Study sample (n)	Study (year)
low ADE, low treatment efficacy, poor well being	0.56 *	Not reported	No comparison state	-	-	SG	Patients: women on chemo (n=28)	Hess et al (2010)
low ADE, low treatment efficacy, poor well being	0.46*	Not reported	No comparison state	-	-	VAS	Patients: women on chemo (n=28)	Hess et al (2010)
low ADE, low treatment efficacy,	0.32 *	Not reported	No comparison state	-	-	SG	Patients: women under	Hess et al (2010)

poor well being							surveillance (n=13)	
low ADE, low treatment efficacy, poor well being	0.43 *	Not reported	No comparison state	-	-	VAS	Patients: women under surveillance (n=13)	Hess et al (2010)
low ADE, low treatment efficacy, poor well being	0.39 *	Not reported	No comparison state	-	-	SG	Oncologists (n=34)	Hess et al (2010)
low ADE, low treatment efficacy, poor well being	0.35 *	Not reported	No comparison state	-	-	VAS	Oncologists (n=34)	Hess et al (2010)
low-moderate ADE, low treatment efficacy, moderate well being	0.53 *	Not reported	No comparison state	-	-	SG	Patients: women on chemo (n=28)	Hess et al (2010)
low-moderate ADE, low treatment efficacy, moderate well being	0.38 *	Not reported	No comparison state	-	-	VAS	Patients: women on chemo (n=28)	Hess et al (2010)
low-moderate ADE, low treatment efficacy, moderate well being	0.34 *	Not reported	No comparison state	-	-	SG	Patients: women under surveillance (n=13)	Hess et al (2010)
low-moderate ADE, low treatment efficacy, moderate well being	0.38 *	Not reported	No comparison state	-	-	VAS	Patients: women under surveillance (n=13)	Hess et al (2010)
low-moderate ADE, low treatment efficacy, moderate well being	0.43*	Not reported	No comparison state	-	-	SG	Oncologists (n=34)	Hess et al (2010)
low-moderate ADE, low treatment efficacy, moderate well being	0.26 *	Not reported	No comparison state	-	-	VAS	Oncologists (n=34)	Hess et al (2010)
moderate-high ADE, moderate treatment efficacy, poor well being	0.53 *	Not reported	No comparison state	-	-	SG	Patients: women on chemo (n=28)	Hess et al (2010)
moderate-high ADE, moderate treatment efficacy, poor well	0.28 *	Not reported	No comparison state	-	-	VAS	Patients: women on chemo (n=28)	Hess et al (2010)

Appendix 3: Utility values for chemotherapy-related adverse events

being								
moderate-high ADE, moderate treatment efficacy, poor well being	0.30 *	Not reported	No comparison state	-	-	SG	Patients: women under surveillance (n=13)	Hess et al (2010)
moderate-high ADE, moderate treatment efficacy, poor well being	0.28 *	Not reported	No comparison state	-	-	VAS	Patients: women under surveillance (n=13)	Hess et al (2010)
moderate-high ADE, moderate treatment efficacy, poor well being	0.50*	Not reported	No comparison state	-	-	SG	Oncologists (n=34)	Hess et al (2010)
moderate-high ADE, moderate treatment efficacy, poor well being	0.38*	Not reported	No comparison state	-	-	VAS	Oncologists (n=34)	Hess et al (2010)
high ADE, moderate treatment efficacy, positive well being	0.56 *	Not reported	No comparison state	-	-	SG	Patients: women on chemo (n=28)	Hess et al (2010)
high ADE, moderate treatment efficacy, positive well being	0.52 *	Not reported	No comparison state	-	-	VAS	Patients: women on chemo (n=28)	Hess et al (2010)
high ADE, moderate treatment efficacy, positive well being	0.37 *	Not reported	No comparison state	-	-	SG	Patients: women under surveillance (n=13)	Hess et al (2010)
high ADE, moderate treatment efficacy, positive well being	0.38 *	Not reported	No comparison state	-	-	VAS	Patients: women under surveillance (n=13)	Hess et al (2010)
high ADE, moderate treatment efficacy, positive well being	0.52 *	Not reported	No comparison state	-	-	SG	Oncologists (n=34)	Hess et al (2010)
high ADE, moderate treatment efficacy, positive well being	0.51*	Not reported	No comparison state	-	-	VAS	Oncologists (n=34)	Hess et al (2010)
extremely high ADE, high treatment	0.61 *	Not reported	No comparison state	-	-	SG	Patients: women on chemo (n=28)	Hess et al (2010)

efficacy, positive well being								
extremely high ADE, high treatment efficacy, positive well being	0.61 *	Not reported	No comparison state	-	-	VAS	Patients: women on chemo (n=28)	Hess et al (2010)
extremely high ADE, high treatment efficacy, positive well being	0.37 *	Not reported	No comparison state	-	-	SG	Patients: women under surveillance (n=13)	Hess et al (2010)
extremely high ADE, high treatment efficacy, positive well being	0.52 *	Not reported	No comparison state	-	-	VAS	Patients: women under surveillance (n=13)	Hess et al (2010)
extremely high ADE, high treatment efficacy, positive well being	0.69 *	Not reported	No comparison state	-	-	SG	Oncologists (n=34)	Hess et al (2010)
extremely high ADE, high treatment efficacy, positive well being	0.66*	Not reported	No comparison state	-	-	VAS	Oncologists (n=34)	Hess et al (2010)
extremely high ADE, high treatment efficacy, poor well being	0.56 *	Not reported	No comparison state	-	-	SG	Patients: women on chemo (n=28)	Hess et al (2010)
extremely high ADE, high treatment efficacy, poor well being	0.46 *	Not reported	No comparison state	-	-	VAS	Patients: women on chemo (n=28)	Hess et al (2010)
extremely high ADE, high treatment efficacy, poor well being	0.30 *	Not reported	No comparison state	-	-	SG	Patients: women under surveillance (n=13)	Hess et al (2010)
extremely high ADE, high treatment efficacy, poor well being	0.37 *	Not reported	No comparison state	-	-	VAS	Patients: women under surveillance (n=13)	Hess et al (2010)
extremely high ADE,	0.63 *	Not reported	No comparison state	-	-	SG	Oncologists	Hess et al

Appendix 3: Utility values for chemotherapy-related adverse events

high treatment efficacy, poor well being							(n=34)	(2010)
extremely high ADE, high treatment efficacy, poor well being	0.52 *	Not reported	No comparison state	-	-	VAS	Oncologists (n=34)	Hess et al (2010)
significant chemotherapy-related side effects	0.63	95% CI: 0.56-0.70	Stage III CRC treated with resection and chemotherapy without significant side effects	0.70	95% CI: 0.63-0.77	SG	Patients: ADE state (n=41) Comparison state (n=40)	Ness et al (1999)

ADE: adverse drug events, HCPs: health care professionals

* approximate as read from graph

[a] base state and utility increments were presented on different scales: base state was based on standard gamble scale between perfect health (arbitrary score of 100) or immediate death (arbitrary score of 0) while the utility increments were based on a scale between perfect health (arbitrary score of 100) and the surrogate negative anchor of continuous nausea/vomiting (re-set to an arbitrary score of 0)

[b] utility values were also presented as utility decrements

[c] sub-sample of the Hutton et al (1996) study

Best JH, Garrison LP, Hollingworth W, Ramsey SD, Veenstra DL. Preference values associated with stage III colon cancer and adjuvant chemotherapy. Quality of life research 2010; 19:391-400.

Beusterien KM, Szabo SM, Kotapati S, Mukherjee J, Hoos A, Hersey P et al. Societal preference values for advanced melanoma health states in the United Kingdom and Australia. British Journal of Cancer 2009; 101(3):387-389.

Beusterien KM, Davies J, Leach M, Meiklejohn D, Grinspan JL, O'Toole A et al. Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study. Health and quality of life outcomes 2010; 8(50).

Brown RE, Hutton J, Burrell A. Cost effectiveness of treatment options in advanced breast cancer in the UK. PharmacoEconomics 2001; 19:1091-1102.

Franic DM, Pathak DS, Gafni A. Are health states 'timeless'? A case study of an acute condition: Post-chemotherapy nausea and vomiting. Journal of Evaluation in Clinical Practice 2003; 9(1):69-82.

Grunberg SM, Srivastava A, Grunberg KJ, Weeks J. Intensity of chemotherapy-induced emesis and overall survival as determinants of a global utility score. Supportive Care in Cancer 2002; 10(8):624-629.

Grunberg SM, Weeks J, Magnan WF, Herndon J, Naughton ML, Blackwell KL et al. Determination of utility scores for control of chemotherapy-induced nausea or vomiting - CALGB 309801. Journal of Supportive Oncology 2009; 7(5):17-22.

Havrilesky LJ, Broadwater G, Davis DM, Nolte KC, Barnett JC, Myers ER et al. Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment. Gynecologic Oncology 2009; 113(2):216-220.

Hess LM, Malone DC, Reed PG, Skrepnek G, Weihs K. Preferences of patients and oncologists for advanced ovarian cancer treatment-related health states. Health Outcomes Research in Medicine 2010; 1(1):51-59.

Hutton J, Brown R, Borowitz M, Abrams K, Rothman M, Shakespeare A. A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer. PharmacoEconomics 1996; 9:8-22.

Leung PP, Tannock IF, Oza AM, Puodziunas A, Dranitsaris G. Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer. Journal of Clinical Oncology 1999; 17(10):3082-3090.

Lloyd A, Nafees B, Narewska J, Dewilde S, Watkins J. Health state utilities for metastatic breast cancer. British Journal of Cancer 2006; 95(6):683-690.

Lloyd A, Van Hanswijck De JP, Doyle S, Cornes P. Health state utility scores for cancer-related anemia through societal and patient valuations. Value in Health 2008; 11(7):1178-1185.

Nafees B, Stafford M, Gavriel S, Bhalla S, Watkins J. Health state utilities for non small cell lung cancer. Health and quality of life outcomes 2008; 6(84).

Ness RM, Holmes AM, Klein R, Dittus R. Utility valuations for outcome states of colorectal cancer. American Journal of Gastroenterology 1999; 94(6):1650-1657.

Nguyen CT, Fu AZ, Gilligan TD, Wells BJ, Klein EA, Kattan MW et al. Defining the optimal treatment for clinical stage I nonseminomatous germ cell testicular cancer using decision analysis. Journal of Clinical Oncology 2010; 28(1):119-125.

Ossa DF, Briggs A, McIntosh E, Cowell W, Littlewood T, Sculpher M. Recombinant erythropoietin for chemotherapy-related anaemia: Economic value and health-related quality-of-life assessment using direct utility elicitation and discrete choice experiment methods. PharmacoEconomics 2007; 25(3):223-237.

Shiroiwa T, Fukuda T, Tsutani K. Health utility scores of colorectal cancer based on societal preference in Japan. Quality of Life Research 2009; 18(8):1095-1103.